This educational lecture by Dr. Prakruthi J. on Rheuma TV provides a comprehensive pharmacological overview of Sulfasalazine (SSZ), a core Conventional Synthetic Disease-Modifying Antirheumatic Drug (csDMARD) used in the management of Rheumatoid Arthritis (RA).
Pharmacokinetics & Metabolism: Explores how oral sulfasalazine acts as a prodrug, cleaved by bacterial azoreductase enzymes in the colon into its active components: sulfapyridine (responsible for systemic immunomodulatory efficacy in RA) and 5-aminosalicylic acid (5-ASA/mesalazine). Covers intestinal absorption, hepatic acetylation (fast vs. slow acetylators), plasma half-life, and route of elimination.
Pharmacodynamics & Mechanisms: Highlights the multifactorial mechanism of action, including inhibition of nuclear factor kappa B (NF-$\kappa$B), blockade of inflammatory cytokines (TNF-$\alpha$, IL-1, IL-6), suppression of B-cell antibody production, and inhibition of folate-dependent enzyme pathways and adenosine signaling.
Clinical Application: Discusses dosing protocols, onset of action, role in monotherapy vs. DMARD combination regimens (e.g., Triple Therapy with Methotrexate and Hydroxychloroquine), along with essential safety, adverse effect profiles, and laboratory monitoring guidelines.